Skip to main
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings is positioned for robust growth, as evidenced by a significant 65% year-over-year increase in core exome/genome revenue and an impressive 33% rise in core testing volumes. The company anticipates a favorable mix-shift towards exome and genome panels, contributing to average selling prices (ASPs) of $3,850 per test, up 23% year-over-year, while also guiding for improved gross margins of 70%-71%. Additionally, GeneDx has raised its 2025 revenue guidance to $425-428 million, reflecting a strong positive outlook driven by the expansion of precision medicine and strategic targeting of pediatric neurologists in its sales approach.

Bears say

GeneDx Holdings Corp is facing a negative outlook due to expected cash burns of approximately $2 million per quarter in 2024, coupled with a high denial rate of 45% for its services, which significantly impacts its revenue generation capabilities. The company's reliance on third-party payers for reimbursement poses a substantial risk, as any amendments or renegotiations in reimbursement schedules could adversely affect its commercial success. Furthermore, challenges in maintaining supply chains for sequencers and the potential for disruptions in data and workflow services could severely hinder its operational efficacy and overall financial stability.

WGS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Strong Buy based on their latest research and market trends.

According to 7 analysts, WGS has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $130.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $130.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.